Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL

Neeraj Saini, David Marin, Celina Ledesma, Ruby Delgado, Gabriela Rondon, Uday R Popat, Qaiser Bashir, Chitra M Hosing, Yago Nieto, Amin M Alousi, Muzaffar H Qazilbash, Stefan Ciurea, Elizabeth Shpall, Issa Khouri, Hagop Kantarjian, Elias Jabbour, Farhad Ravandi, Richard E Champlin, Partow Kebriaei, Neeraj Saini, David Marin, Celina Ledesma, Ruby Delgado, Gabriela Rondon, Uday R Popat, Qaiser Bashir, Chitra M Hosing, Yago Nieto, Amin M Alousi, Muzaffar H Qazilbash, Stefan Ciurea, Elizabeth Shpall, Issa Khouri, Hagop Kantarjian, Elias Jabbour, Farhad Ravandi, Richard E Champlin, Partow Kebriaei

Abstract

Publisher's Note: There is a Blood Commentary on this article in this issue.

Conflict of interest statement

Conflict-of-interest disclosure: P.K. has received research support from Amgen and Ziopharm; has served on advisory boards of Pfizer, Kite, and Novartis; and has received consulting fees from Jazz. F.R. has received research funding from BMS, Amgen, Xencor, Abbvie, and Orsenix; has served on advisory boards of BMS, Amgen, Astellas, AstraZeneca, Celgene, Orsenix, and Agios; and has received honoraria from BMS, Celgene, Astellas, Abbvie, AstraZeneca, Novartis, Orsenix, and Agios. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Study outcomes and practice patterns. (A) PFS and OS for the whole cohort of patients with Ph+ ALL. (B) PFS and OS for patients with Ph+ ALL who underwent allo-HCT while in CR1. (C) Dot matrix chart showing percentage of patients receiving different types of TKI. (D) Landmark analysis of patients who were in CMR status before and at 3 months after allo-HCT, with a significantly higher PFS in patients who received prophylactic TKI therapy compared with those who did not. (E) Graph showing increased incidence of relapse in patients who discontinued TKI therapy before 24 months vs those who continued for >24 months. (F) Decreasing percentage of patients who underwent transplantation while in CR1 over time.

References

    1. Abou Dalle I, Jabbour E, Short NJ, Ravandi F. Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Curr Treat Options Oncol. 2019;20(1):4.
    1. Warraich Z, Tenneti P, Thai T, et al. . Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Ph+ ALL, A Systematic Review. Biol Blood Marrow Transplant. 2020;26(3):e55-e64.
    1. Giebel S, Czyz A, Ottmann O, et al. . Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2016;122(19):2941-2951.
    1. Litzow MR. Allogeneic transplantation for patients with Philadelphia chromosome positive acute lymphoblastic leukemia: is it imperative in the tyrosine kinase inhibitor era? Best Pract Res Clin Haematol. 2018;31(4):357-360.
    1. Carpenter PA, Snyder DS, Flowers MED, et al. . Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood. 2007;109(7):2791-2793.
    1. Akahoshi Y, Nishiwaki S, Mizuta S, et al. ; Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation . Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer Sci. 2019;110(10):3255-3266.
    1. Chen H, Liu K-Y, Xu L-P, et al. . Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. J Hematol Oncol. 2012;5:29.
    1. Brissot E, Labopin M, Beckers MM, et al. . Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica. 2015;100(3):392-399.
    1. Zhang FH, Ling YW, Zhai X, et al. . The effect of imatinib therapy on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology. 2013;18(3):151-157.
    1. Pfeifer H, Wassmann B, Bethge W, et al. ; GMALL Study Group . Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia. 2013;27(6):1254-1262.
    1. Kebriaei P, Saliba R, Rondon G, et al. . Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. Biol Blood Marrow Transplant. 2012;18(4):584-592.
    1. Short NJ, Jabbour E, Sasaki K, et al. . Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016;128(4):504-507.
    1. Soverini S, Vitale A, Poerio A, et al. . Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. Haematologica. 2011;96(4):552-557.
    1. Soverini S, De Benedittis C, Papayannidis C, et al. . Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: the main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer. 2014;120(7):1002-1009.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit